Segall Bryant & Hamill, LLC Gilead Sciences, Inc. Transaction History

Segall Bryant & Hamill, LLC

$7.16 Billion
Q3 2024

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 09, 2023	BUY	$73.94 - $80.67 $3,623 - $3,952	49 Added 0.48%	10,298 $771,000
Q2 2023 Aug 11, 2023	BUY	$76.01 - $86.7 $76 - $86	1 Added 0.01%	10,249 $789,000
Q1 2023 May 15, 2023	SELL	$77.31 - $88.08 $3,633 - $4,139	-47 Reduced 0.46%	10,248 $850,000
Q4 2022 Feb 14, 2023	SELL	$62.32 - $89.47 $5,733 - $8,231	-92 Reduced 0.89%	10,295 $883,000
Q3 2022 Nov 14, 2022	BUY	$59.54 - $68.01 $5,477 - $6,256	92 Added 0.89%	10,387 $641,000
Q2 2022 Aug 15, 2022	SELL	$57.72 - $65.01 $1,500 - $1,690	-26 Reduced 0.25%	10,295 $636,000
Q1 2022 May 13, 2022	SELL	$57.92 - $72.58 $234,576 - $293,949	-4,050 Reduced 28.18%	10,321 $613,000
Q4 2021 Feb 14, 2022	SELL	$64.88 - $73.64 $15,506 - $17,599	-239 Reduced 1.64%	14,371 $1.04 Million
Q3 2021 Nov 03, 2021	BUY	$67.69 - $73.03 $12,793 - $13,802	189 Added 1.31%	14,610 $1.02 Million
Q2 2021 Aug 12, 2021	SELL	$63.47 - $69.35 $944,179 - $1.03 Million	-14,876 Reduced 50.78%	14,421 $993,000
Q1 2021 May 13, 2021	BUY	$60.0 - $68.46 $929,220 - $1.06 Million	15,487 Added 112.14%	29,297 $1.89 Million
Q4 2020 Feb 12, 2021	SELL	$56.65 - $64.55 $21,470 - $24,464	-379 Reduced 2.67%	13,810 $804,000
Q3 2020 Nov 13, 2020	SELL	$62.1 - $78.08 $199,465 - $250,792	-3,212 Reduced 18.46%	14,189 $896,000
Q2 2020 Aug 14, 2020	BUY	$72.34 - $84.0 $102,578 - $119,112	1,418 Added 8.87%	17,401 $1.34 Million
Q1 2020 May 14, 2020	SELL	$62.63 - $80.22 $137,535 - $176,163	-2,196 Reduced 12.08%	15,983 $1.19 Million
Q4 2019 Feb 11, 2020	SELL	$61.62 - $67.78 $2,464 - $2,711	-40 Reduced 0.22%	18,179 $1.18 Million
Q2 2019 Aug 14, 2019	BUY	$61.87 - $69.38 $139,578 - $156,521	2,256 Added 14.13%	18,219 $0
Q1 2019 May 15, 2019	SELL	$62.53 - $70.05 $4,314 - $4,833	-69 Reduced 0.43%	15,963 $0
Q4 2018 Feb 15, 2019	SELL	$60.54 - $79.0 $10,957 - $14,299	-181 Reduced 1.12%	16,032 $1 Million
Q3 2018 Nov 14, 2018	SELL	$71.28 - $78.92 $211,060 - $233,682	-2,961 Reduced 15.44%	16,213 $0
Q2 2018 Aug 08, 2018	BUY	$64.88 - $75.68 $353,401 - $412,228	5,447 Added 39.68%	19,174 $0
Q1 2018 May 16, 2018	SELL	$72.84 - $88.8 $14,568 - $17,760	-200 Reduced 1.44%	13,727 $0
Q4 2017 Feb 15, 2018	SELL	$71.15 - $83.52 $466,103 - $547,139	-6,551 Reduced 31.99%	13,927 $0
Q3 2017 Nov 14, 2017	BUY	$72.11 - $85.47 $1.48 Million - $1.75 Million	20,478	20,478 $0

Others Institutions Holding GILD

# of Institutions

1,927

Shares Held

994M

Call Options Held

10.5M

Put Options Held

9.75M

Black Rock Inc. New York, NY

121M
Shares

$11.2 Billion
0.19% of portfolio
Vanguard Group Inc Valley Forge, PA

115M
Shares

$10.7 Billion
0.18% of portfolio
Capital World Investors Los Angeles, CA

76.5M
Shares

$7.09 Billion
1.03% of portfolio
Capital Research Global Investors Los Angeles, CA

61.8M
Shares

$5.72 Billion
1.12% of portfolio
State Street Corp Boston, MA

60.2M
Shares

$5.57 Billion
0.21% of portfolio

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Segall Bryant & Hamill, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Segall Bryant & Hamill, LLC with notifications on news.

Account